Arrhythmias & electrophysiology
Long-term antithrombotic therapy after coronary artery bypass grafting in patients with preoperative atrial fibrillation. A nationwide observational study from the SWEDEHEART registry
Authors' conclusion
In this real-world observational study, a high proportion of patients with AF, undergoing CABG, did not receive a long-term OAC therapy. Treatment with OAC alone was associated with a net clinical benefit, compared with PI alone or PI + OAC.
Study context
- Population
- Patients with preoperative atrial fibrillation (AF) and CHA2DS2-VASC score ≥2 undergoing CABG, SWEDEHEART registry, January 2006–September 2016
- Participants
- 2,564 patients
- Exposure
- Platelet inhibitors (PI) alone vs oral anticoagulant (OAC) alone vs PI + OAC
- PIn = 1,040
- OACn = 1,064reference
- PI + OACn = 460
- Outcome
- Major adverse cardiac and cerebrovascular events (MACCE) (all-cause death, MI or stroke); Net adverse clinical events (NACE) (MACCE or bleeding)
Methodological detailsnationwide, registry-based, inverse probability of treatment weighting
- Nationwide
- Registry-based
- Inverse probability of treatment weighting
Main finding
As reported in the abstract
Each group vs OACAdjusted hazard ratio (95% CI)
PIMACCE; driven by stroke and MI
1.43(1.09–1.88)
PI + OACNACE; driven by bleeds
1.40(1.06–1.85)
Observational data: associations, not effects.
Original publication
Long-term antithrombotic therapy after coronary artery bypass grafting in patients with preoperative atrial fibrillation. A nationwide observational study from the SWEDEHEART registry. Am Heart J. Published 5 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →